Phaseline

Companies › SecuraBio

SecuraBio: clinical trials, targets and expected readouts

1 active drug program in 13 registered trials: 7 Phase 1, 5 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Duvelisib
PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor
PIK3CD, PIK3CGPhase 3Lymphoma; Newly Diagnosed Peripheral T-cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Recurrent Chronic Lymphocytic Leukemia …Feb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05976997DuvelisibPhase 2Newly Diagnosed Peripheral T-cell LymphomaOncologyDec 2026
NCT02158091DuvelisibPhase 1Chronic Lymphocytic LeukemiaOncologyDec 2026
NCT04803201DuvelisibPhase 2Angioimmunoblastic T-cell LymphomaOncologyMay 2027
NCT05010005DuvelisibPhase 1T-cell LymphomasOncologyAug 2027
NCT03961672DuvelisibPhase 2Recurrent Chronic Lymphocytic LeukemiaOncologyOct 2027
NCT06522737DuvelisibPhase 3LymphomaOncologyFeb 2028
NCT04652960DuvelisibPhase 1Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8OncologyJun 2028
NCT06530550DuvelisibPhase 2Lymphoma, T-CellOncologyJul 2028
NCT05675813DuvelisibPhase 1Peripheral T Cell LymphomaOncologyJul 2028
NCT07293403DuvelisibPhase 2Follicular Helper T-Cell LymphomaOncologySep 2028
NCT05044039DuvelisibPhase 1Non-Hodgkin LymphomaOncologyMay 2030
NCT06810778DuvelisibPhase 1T-cell-prolymphocytic LeukemiaOncologyJun 2030
NCT07001384DuvelisibPhase 1Anaplastic Lymphoma KinaseOncologyAug 2031

Targets

PIK3CD (1) PIK3CG (1)

Companies with the same targets

Rhizen Pharmaceuticals Incyte Biosciences Japan GK Pharming Technologies Incyte Kyowa Kirin Restorbio Celcuity Eli Lilly Sovargen Stelexis BioSciences

Companies built like this

Rhizen Pharmaceuticals Verity Pharmaceuticals Fidia Farmaceutici Sumitomo Pharma Switzerland Eleison Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.